Connexin 43 expression in the testes during postnatal development of finasteride-treated male rat offspring

Finasteride-Induced Inhibition of 5α-Reductase Type 2 Could Lead to Kidney Damage-Animal, Experimental Study

In the pharmacological treatment of prostate cancer, benign prostatic hyperplasia and androgenetic alopecia finasteride is commonly used. This drug inhibits 5α-reductase type 2, which is why finasteride affects androgen homeostasis, since testosterone (T) cannot be reduced to dihydrotestosterone (DHT). As studies on sex-related renal injuries suggest a high probability of androgen-induced renal dysfunction, the aim of this study was to determine the potential harmful effects of finasteride on the kidneys of rats. The study was performed on sexually mature male Wistar rats given finasteride. Histological sections of the kidneys were used for immunohistochemical visualization of the androgen receptor (AR), junctional proteins (occluding (Occ); E-cad, N-cad, E-/N-cadherin; β-cat, β-catenin; connexin 43 (Cx43)), proliferating cell nuclear antigen (PCNA), IL-6, and lymphocyte markers (CD3 for T cell, CD19 for B cell). The TUNEL method was used for cell apoptosis identification, and picro sirius red staining was used to assess collagen fibers thickness. The levels of T, DHT and estradiol (E2) were determined in blood serum. It was shown that finasteride treatment affected steroid hormone homeostasis, altered the expression of AR and intracellular junction proteins, changed the ratio between cell apoptosis and proliferation, and caused lymphocyte infiltration and an increase of IL-6. The thickening of collagen fibers was observed as tubular fibrosis and glomerulosclerosis. Summarizing, finasteride-induced hormonal imbalance impaired the morphology (i.e., dysplastic glomeruli, swollen proximal convoluted tubules) and physiology (changed level of detected proteins/markers expression) of the kidneys. Therefore, it is suggested that patients with renal dysfunction or following renal transplantation, with androgen or antiandrogen supplementation, should be under special control and covered by extended diagnostics, because the adverse negative effect of DHT deficiency on the progression of kidney disease cannot be ignored.

Antioxidant enzyme expression of mRNA and protein in the epididymis of finasteride-treated male rat offspring during postnatal development

INTRODUCTION

We verify whether finasteride had a transgenerational effect on the epididymal expression of antioxidant enzymes, and the correlation between these enzymes and blood androgen concentrations in male offspring (F1:Fin) of females fertilized by finasteride-treated male rats.

MATERIAL AND METHODS

The expression of CAT, SOD1, GPX5, GR on the mRNA and protein levels was evaluated in the epididymis at postnatal day (PND) 7, 14, 21, 28 and 90. Levels of T and DHT were correlated with mRNA levels of enzymes by Spearman's rank correlation coefficient.

RESULTS

A change in the levels of transcripts was noted in F1:Fin rats: CAT decreased at PND 28 (p < 0.01) and increased at PND 90 (p < 0.01); SOD1 increased at PND 7 (p < 0.0001), 21 (p < 0.001), 90 (p < 0.0001) and decreased at 14 PND (p < 0.01); GPX5 increased at PND 14 and 21 (p < 0.0001); GR decreased at PND 21 and 28 (p < 0.0001). Altered immunolocalization of enzymes within the epididymal epithelium was observed. Negative correlations between GPX5 mRNA with androgens (T, p = 0.0002; DHT, p = 0.0009) were visible in the control rats, and positive correlation between DHT and CAT mRNA (p = 0.03), in opposite to F1:Fin group were was negative for both androgens (T, p = 0.044 and DHT, p = 0.02).

CONCLUSIONS

Finasteride treatment of adult male rats may cause changes in antioxidant defense system in the epididymis of their offspring, leading to improper ROS concentrations that can affect post-testicular sperm maturation.

Long-term treatment with finasteride induces apoptosis and pathological changes in female mice

Androgenetic alopecia is the most common type of alopecia, and it affects humans of both genders. Finasteride is a type II selective 5α-reductase inhibitor that is administered orally to treat androgenetic alopecia and benign prostatic hyperplasia in human males. However, its effect on the vital organs of females is unknown. This study was designed to investigate the effects of finasteride on the vital organs such as liver, kidney, and heart of female mice. To study the prospective effects of finasteride, female mice were orally administered two doses of finasteride (0.5 and 1.5 mg/kg) once daily for 35 days, and serum levels of various biochemical parameters and histopathology of various organs were examined. The results showed that serum levels of alkaline phosphatase were significantly increased by both high- and low-dose finasteride, whereas cholesterol was significantly increased by the high dose only. Creatine kinase was significantly increased by the high and low doses, whereas glucose was significantly decreased by both doses. Histopathological analysis and DNA damage assays showed that finasteride has adverse effects within both the short and the long periods in female mice. In addition, the proapoptotic genes Bax and caspase-3 were significantly increased by high dose finasteride, whereas the antiapoptotic gene Bcl-2 was significantly decreased by the low and high doses. In conclusion, finasteride is not currently approved for therapeutic use in females, and the findings in this study suggest caution in any future consideration of such use.